[go: up one dir, main page]

HUP9801075A2 - Kombinált állandó dózisú angiotenzint átalakító enzim inhibítor kalciumcsatorna-antagonista, eljárás ennek előállítására, valamint alkalmazása szív- és érrendszeri betegségek kezelésében - Google Patents

Kombinált állandó dózisú angiotenzint átalakító enzim inhibítor kalciumcsatorna-antagonista, eljárás ennek előállítására, valamint alkalmazása szív- és érrendszeri betegségek kezelésében

Info

Publication number
HUP9801075A2
HUP9801075A2 HU9801075A HUP9801075A HUP9801075A2 HU P9801075 A2 HUP9801075 A2 HU P9801075A2 HU 9801075 A HU9801075 A HU 9801075A HU P9801075 A HUP9801075 A HU P9801075A HU P9801075 A2 HUP9801075 A2 HU P9801075A2
Authority
HU
Hungary
Prior art keywords
dose
calcium channel
enzyme inhibitor
preparation
treatment
Prior art date
Application number
HU9801075A
Other languages
English (en)
Inventor
Perdo Cánovas Soler
Joaquin Delgadillo Duarte
Luis Manuel Micheto Escuder
Original Assignee
Vita-Invest, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8299270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9801075(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vita-Invest, S.A. filed Critical Vita-Invest, S.A.
Publication of HU9801075D0 publication Critical patent/HU9801075D0/hu
Publication of HUP9801075A2 publication Critical patent/HUP9801075A2/hu
Publication of HUP9801075A3 publication Critical patent/HUP9801075A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány egy angiőtenzin kőnvertáló enzim inhibitőr és egykalciűmcsatőrna-antagőnista meghatárőzőtt dózisú kőmbinációja, azzaljelemezve, hőgy a) enalapril vagy gyógyászatilag alkalmazható sójánakegy dózisát és b) nitrendipin vagy gyógyászatilag alkalmazható sójánakegy másik dózisát tartalmazza, és a kőmbináció egyszeri dózisúgalenűsi készítmény főrmájában alkalmazandó. A találmány tárgyát képezi a fenti kőmbinációt tartalmazó gyógyászatikészítmények, tővábbá annak előállítására szőlgáló eljárás. ŕ
HU9801075A 1997-05-13 1998-05-12 Fixed-dose association of an angiotensinconverting enzyme inhibitor and of a calcium channel antagonist, method for preparation and use thereof in the treatment of cardiovascular illnesses HUP9801075A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009701017A ES2125198B1 (es) 1997-05-13 1997-05-13 Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.

Publications (3)

Publication Number Publication Date
HU9801075D0 HU9801075D0 (en) 1998-07-28
HUP9801075A2 true HUP9801075A2 (hu) 1999-01-28
HUP9801075A3 HUP9801075A3 (en) 2000-12-28

Family

ID=8299270

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801075A HUP9801075A3 (en) 1997-05-13 1998-05-12 Fixed-dose association of an angiotensinconverting enzyme inhibitor and of a calcium channel antagonist, method for preparation and use thereof in the treatment of cardiovascular illnesses

Country Status (23)

Country Link
EP (1) EP0884054B9 (hu)
JP (1) JP3576806B2 (hu)
CN (1) CN1146418C (hu)
AR (1) AR011730A1 (hu)
AT (1) ATE236653T1 (hu)
AU (1) AU735404B2 (hu)
BR (1) BR9805597A (hu)
CA (1) CA2234899C (hu)
CZ (1) CZ292616B6 (hu)
DE (1) DE69813083T2 (hu)
DK (1) DK0884054T3 (hu)
ES (2) ES2125198B1 (hu)
HU (1) HUP9801075A3 (hu)
IL (1) IL124253A (hu)
NO (1) NO315545B1 (hu)
NZ (1) NZ330447A (hu)
PL (1) PL192117B1 (hu)
PT (1) PT884054E (hu)
RU (1) RU2182002C2 (hu)
SK (1) SK284337B6 (hu)
TR (1) TR199800847A3 (hu)
TW (1) TW562679B (hu)
ZA (1) ZA983806B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226950B1 (en) * 1999-11-03 2010-03-29 Richter Gedeon Nyrt The magnesium salt of enalapril and antihypertensive pharmaceutical composition containing it
ATE363281T1 (de) * 2000-04-11 2007-06-15 Sankyo Co Stabilisierte pharmazeutische zusammenstellungen die den calziumkanalblocker azelnidipine enthalten
MEP27808A (en) * 2001-01-26 2010-10-10 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
RS58025B1 (sr) * 2002-12-16 2019-02-28 Kissei Pharmaceutical Co Ltd Lekovi u čvrstom stanju za oralnu upotrebu
RU2618471C2 (ru) * 2012-12-03 2017-05-03 Закрытое Акционерное Общество "Вертекс" Пероральная фармацевтическая композиция диуретика и ингибитора АПФ в микронизированной форме, лекарственное средство и его применение
CN109350733A (zh) * 2018-06-08 2019-02-19 山东理工职业学院 一种马来酸依那普利片剂的制备方法
CN109985013B (zh) * 2019-05-10 2021-08-10 河北君圣药业有限公司 一种尼群地平分散片及其制备方法
CN115501224A (zh) * 2022-10-09 2022-12-23 南昌大学第一附属医院 马来酸依那普利叶酸片联合通心络在制备治疗高血压合并颈动脉硬化药物的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3437917A1 (de) * 1984-10-17 1986-04-17 Bayer Ag, 5090 Leverkusen Kombination von dihydropyridinen mit ace-hemmern sowie ihre verwendung in arzneimitteln
USH734H (en) * 1988-03-07 1990-02-06 E. R. Squibb & Sons, Inc. Method for inhibiting onset of or treating migraine headaches employing an ACE inhibitor
JPH01275529A (ja) * 1988-03-21 1989-11-06 E R Squibb & Sons Inc 晩発性運動障害の抑制治療剤
CA2007525A1 (en) * 1989-01-30 1990-07-30 Zola P. Horovitz Method for facilating dieting employing an ace inhibitor
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
SI9111842A (sl) * 1991-11-25 1998-04-30 Krka Stabilna formulacija soli enalaprila, postopek za njeno pripravo in njena uporaba
SI9300504A (en) * 1993-09-28 1995-04-30 Krka Process for preparation solid dispersions and deposits of calcium antagonist dihidropyrimidine derivates and pharmaceutical compositions comprising the same
US5573780A (en) * 1995-08-04 1996-11-12 Apotex Usa Inc. Stable solid formulation of enalapril salt and process for preparation thereof

Also Published As

Publication number Publication date
NO982112L (no) 1998-11-16
HU9801075D0 (en) 1998-07-28
IL124253A (en) 2003-01-12
BR9805597A (pt) 2000-04-11
DK0884054T3 (da) 2003-07-21
ES2125198A1 (es) 1999-02-16
EP0884054B9 (en) 2007-02-14
AR011730A1 (es) 2000-08-30
EP0884054B1 (en) 2003-04-09
PT884054E (pt) 2003-08-29
DE69813083D1 (de) 2003-05-15
NO315545B1 (no) 2003-09-22
PL326246A1 (en) 1998-11-23
AU735404B2 (en) 2001-07-05
CA2234899C (en) 2004-08-10
SK61698A3 (en) 1998-12-02
TR199800847A2 (xx) 1999-10-21
DE69813083T2 (de) 2004-05-27
EP0884054A3 (en) 2000-08-23
NZ330447A (en) 1998-12-23
AU6597398A (en) 1998-11-19
CZ138198A3 (cs) 1998-12-16
RU2182002C2 (ru) 2002-05-10
JPH11124330A (ja) 1999-05-11
ES2197443T3 (es) 2004-01-01
CN1146418C (zh) 2004-04-21
PL192117B1 (pl) 2006-09-29
CN1212869A (zh) 1999-04-07
EP0884054A2 (en) 1998-12-16
SK284337B6 (sk) 2005-02-04
ES2125198B1 (es) 1999-11-16
HUP9801075A3 (en) 2000-12-28
CA2234899A1 (en) 1998-11-13
NO982112D0 (no) 1998-05-08
JP3576806B2 (ja) 2004-10-13
CZ292616B6 (cs) 2003-11-12
TR199800847A3 (tr) 1999-10-21
ATE236653T1 (de) 2003-04-15
ZA983806B (en) 1999-02-19
TW562679B (en) 2003-11-21

Similar Documents

Publication Publication Date Title
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
MY119489A (en) Novel pharmaceutical composition containing the ace inhibitor ramipril and a dihydropyridine compound
MY128809A (en) Pharmaceutical formulation of omeprazole
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
EE04417B1 (et) Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm, selle valmistamise meetod ja kasutamine
ATE265857T1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
HUP9802315A3 (en) Thrombin inhibitors, process for producing them and use of them for producing pharmaceutical compositions
HUP9602507A3 (en) Cyclic peptides, adhesion inhibitor pharmaceutical compositions comprising the compounds, process for the preparation of the compounds and the pharmaceutical compositions and the use of the compounds
NO20061736L (no) Krystallform av epotilon B
HUP0102250A3 (en) Compounds of unstable dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
FI973039A0 (fi) Uusia farnesyylitransferaasin inhibiittoreita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
FI20011703A7 (fi) Jodidia ja jodaattia sisältävä stabiloitu oraalinen farmaseuttinen koostumus sekä menetelmä
AU2002212395A1 (en) Method and preparation for binding acetaldehyde in saliva, stomach and large intestine
DE69033970D1 (de) Huperzin a analoge verbindungen
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
HUP9801075A2 (hu) Kombinált állandó dózisú angiotenzint átalakító enzim inhibítor kalciumcsatorna-antagonista, eljárás ennek előállítására, valamint alkalmazása szív- és érrendszeri betegségek kezelésében
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
EE200100544A (et) 15-lülilised 8a- ja 9a-laktaamid, nende valmistamismeetod ja farmatseutiline kompositsioon
WO2002053099A3 (en) Methods and compositions for treating periodontal disease
FI960284A7 (fi) Uudet merkaptoalkanoyylidipeptidiyhdisteet, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
ATE326954T1 (de) Transdermales therapeutisches system zur verabreichung von calciumantagonisten
AU2003255429A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
FR2752731B1 (fr) Composition utile notamment en chirurgie dentaire

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: FERRER INTERNACIONAL, S.A., ES

Free format text: FORMER OWNER(S): LABORATORIOS VITA, S.A., ES; PROCTER & GAMBLE PHARMACEUTICALS S.A.R.L., CH; PROCTER & GAMBLE PHARMACEUTICALS S.A.R.L., CH; VITA-INVEST, S.A., ES

GB9A Succession in title

Owner name: FERRER INTERNACIONAL, S.A., ES

Free format text: FORMER OWNER(S): FERRER INTERNACIONAL, S.A., ES; LABORATORIOS VITA, S.A., ES; PROCTER & GAMBLE PHARMACEUTICALS S.A.R.L., CH; PROCTER & GAMBLE PHARMACEUTICALS S.A.R.L., CH; PROCTER & GAMBLE PHARMACEUTICALS S.A.R.L., CH; VITA-INVEST, S.A., ES

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished